AUGO vs NEU

The deterministic health scores raise significant concerns, with a Piotroski F-Score of 4/9 indicating marginal financial health and no available Altman Z-Score to confirm safety from distress. Despite strong revenue growth and high operating margins, the company reports negative profit margins and ROE, alongside a dangerously high payout ratio of 780%, suggesting dividends are unsustainable. The stock trades at a steep valuation premium with a Price/Book of 17.69 and Forward P/E of 12.98, while recent earnings have consistently missed estimates—0 out of the last 4 beats and an average surprise of -86.59%. Although analyst consensus is 'strong_buy', price momentum appears disconnected from fundamentals, increasing downside risk.

NEU exhibits strong fundamental health with a Piotroski F-Score of 7/9 and robust liquidity, but it is currently trading at a significant premium to its deterministic value. The current price of $675.62 far exceeds both the Graham Number ($430.75) and the growth-based Intrinsic Value ($306.46). While profitability remains high with an ROE of 25.27%, the company is facing a growth contraction with negative YoY revenue and earnings growth. Consequently, the stock appears overvalued despite its operational quality.